Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

GSK Agrees in Principle to Increase its Stake in GlaxoSmithKline Consumer Nigeria PLC

Published: Monday, November 26, 2012
Last Updated: Monday, November 26, 2012
Bookmark and Share
GSK plc and GSK Consumer Nigeria PLC announced that they have reached agreement in principle on the terms of a proposal whereby GSK would increase its ownership in the Company from 46.4% to 80%.

A minimum public shareholding of 20% is required for a company to maintain a listing on the Nigerian Stock Exchange.

Under the terms of the Proposal, GSK would acquire approximately 321 million shares in the Company on a pro rata basis from public shareholders, at an offer price of NGN 48 per share.  It is intended that the Proposal be effected by way of a Scheme of Arrangement.

GSK Nigeria is engaged in the manufacture, marketing and distribution of a wide range of Consumer Healthcare brands including Panadol, Sensodyne, Horlicks and Lucozade.  In addition the Company also sells several pharmaceutical products including antibiotics such as Augmentin and vaccines. Approximately 70% of the revenue is from Consumer Healthcare Brands and 30% from Pharmaceuticals and Vaccines.

The Proposal represents a premium of 28% to the Company’s closing share price on 23 November, 2012.  The total value of the transaction at the offer price is approximately NGN 15.4 billion (£62 million).

Chief Olusegun Osunkeye, Chairman, GSK Nigeria said: “The Board of Directors unanimously believes that the Proposal is in the best interests of the continued growth of the Company, the shareholders, employees and customers, the community and Nigeria and intends to recommend it to shareholders.”

David Redfern, Chief Strategy Officer, GSK said: “This Proposal to increase GSK’s ownership of GlaxoSmithKline Consumer Nigeria reiterates our long term support of the Company’s strategy and our confidence in the continuing growth prospects of the business.”

The transaction will be funded through GSK’s existing cash resources, will be modestly earnings accretive immediately, and will not impact expectations for the Group’s long-term share buyback programme.

The Company generated turnover of over NGN 21.5 billion in 2011 with a Compound Annual Growth Rate (CAGR) over the past four years of 21%.

The Proposal will be subject to requisite shareholder, regulatory and Court approvals including those of The Nigerian Stock Exchange and the Securities and Exchange Commission.

Citigroup Global Markets Limited is acting as financial adviser to GSK.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Tuesday, September 20, 2016
GSK Presents Positive Results From Phase III Study
GSK reports positive results from phase III FULFIL study of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in COPD.
Friday, September 09, 2016
GSK, Verily establish Galvani Bioelectronics
Following a GSK, Verily agreement, Galvani Bioelectronics will be formed with £540M investment to advance bioelectronic medicines.
Tuesday, August 02, 2016
GSK Announces £275M UK Investment
GSK has announced £275 million of new manufacturing site investment to boost production and support product delivery.
Friday, July 29, 2016
GSK’s RA Trail Using Apple’s ResearchKit
GSK is the first pharmaceutical company to start a trail using Apple’s ResearchKit. They hope to gathering data on rheumatoid arthritis.
Wednesday, July 20, 2016
GSK, Zymeworks Collaborate
Focus on the research, development, and commercialization of novel Fc-engineered monoclonal and bi-specific antibody therapeutics which have been optimized for specific therapeutic effects.
Friday, December 04, 2015
GSK, Idera to Collaborate
Idera to collaborate with GSK to identify 3rd generation antisense molecules for treatment of renal disease.
Monday, November 30, 2015
GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment
Phase I first-in-human study to evaluate GSK’s OX40 agonist GSK3174998 as monotherapy and in combination with Merck’s anti-PD-1 therapy, Keytruda® (pembrolizumab).
Friday, November 06, 2015
GSK, UNC-Chapel Hill Launch $20M HIV Partnership
This new collaboration will be focused on curing HIV through a jointly-owned new company and a research center.
Tuesday, May 12, 2015
GSK to Establish Global Vaccines R&D Centre in the US
New hub based in Rockville, MD expands GSK’s global vaccines R&D footprint.
Thursday, April 09, 2015
GSK Awarded Up to $200 Million by U.S. Government to Develop New Antibiotics
Funding will support development of drugs to fight antibiotic resistance and bioterrorism.
Friday, May 24, 2013
GSK Launches Discovery Fast Track Competition for Academic Researchers
Scientists in U.S., Canada challenged to submit groundbreaking research proposals for chance at collaborative partnership focused on drug discovery.
Wednesday, May 22, 2013
GSK and Impax Pharmaceuticals Terminate Their Collaboration on IPX066
Both Companies end collaboration for the development and commercialization of IPX066 outside the United States and Taiwan.
Tuesday, May 07, 2013
GSK and Impax Terminate Their Collaboration
The companies are terminating their collaboration for the development and commercialisation of IPX066 outside the United States and Taiwan.
Tuesday, April 30, 2013
FDA Approves GlaxoSmithKline’s Four-Strain Seasonal Influenza Vaccine for Use in the US
FLUARIX® QUADRIVALENT is for the immunisation of children (3+) and adults to help prevent disease caused by seasonal influenza (flu) virus subtypes A and type B contained in the vaccine.
Thursday, December 20, 2012
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Transporting Microscopic Cargo Between Human Cells
Scientists have developed a virus-inspired delivery system for material transport between cells.
New Form of Autism Found
An international team of researchers have identified a new form of syndromic autism.
Radiation-Free Imaging in the Brain
Scientists create sensors that use proteins to detect particular targets through induced blood flow changes.
Survey of New York City Soil Uncovers Medicine-Making Microbes
Microbes have long been an invaluable source of new drugs. And to find more, we may have to look no further than the ground beneath our feet.
BGI Sequences Gingko Tree, Revealing Large, Highly Repetitive Genome
Researchers at BGI have sequenced the more than 10-gigabase ginkgo genome to find a high number of repetitive sequences as well as a number of gene clusters that appear to be involved in defense mechanisms.
Accelerating the Detection of Foodborne Bacterial Outbreaks
The speed of diagnosis of foodborne bacterial outbreaks could be improved by a new technique developed by researchers at the Georgia Institute of Technology.
Making Personalized Medicine a Reality
Groundbreaking technique developed at McMaster University is helping to pave the way for advances in personalized medicine.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!